Insider Trading March 16, 2026

Senseonics Director Purchases $100,275 in Stock Amid Weak Share Performance

Douglas Roeder adds 17,500 shares as company reports mixed Q4 2025 results and faces investor scrutiny

By Avery Klein SENS
Senseonics Director Purchases $100,275 in Stock Amid Weak Share Performance
SENS

Senseonics Holdings director Douglas A. Roeder purchased 17,500 shares of the company's common stock on March 13, 2026, paying $5.73 per share for a total outlay of $100,275. The transaction was disclosed in a Form 4 filing and follows a difficult 12-month period for the stock, which has fallen more than 52% and recently traded near a 52-week low. The company also reported fourth-quarter 2025 results that show strong revenue growth but continued losses and rising operating costs.

Key Points

  • Director Douglas A. Roeder bought 17,500 shares at $5.73 each on March 13, 2026, totaling $100,275; post-transaction direct ownership is 119,731 shares.
  • Senseonics reported Q4 2025 revenue of $14.3 million, a 72% increase year-over-year, but posted an EPS loss of $0.46 and an EBIT loss of $21 million.
  • Analyst reaction includes Stifel maintaining a Hold rating with a $9.00 price target, highlighting concerns about cash burn despite gross margins beating expectations.

Summary: Senseonics Holdings director Douglas A. Roeder bought 17,500 shares of the company's common stock at $5.73 per share on March 13, 2026, for a total of $100,275, according to a Form 4 filing with the Securities and Exchange Commission. The purchase occurred while the stock was trading close to its 52-week low, and follows a year in which shares have fallen by more than half. The company recently released fourth-quarter 2025 results that combined substantial top-line growth with continued net losses and higher operating expenses.

Insider purchase details

The Form 4 filing shows the transaction took place on March 13, 2026. After the acquisition, Roeder directly holds 119,731 shares of Senseonics common stock. The 17,500-share buy was completed at $5.73 per share, bringing the transaction value to $100,275. At the time of the trade the market had the stock trading near a 52-week low of $5.25, reflecting a year-over-year decline in excess of 52 percent.

Market context and valuation note

Public commentary included an InvestingPro assessment referenced in company coverage that labels the shares as appearing undervalued with a reported trading level of $6.26. The InvestingPro material is cited as a resource for deeper valuation analysis and additional research material.

Earnings and analyst reaction

Senseonics disclosed its fourth-quarter 2025 financial results showing revenue of $14.3 million, representing a 72 percent increase from the year-ago quarter. Despite the strong revenue gain, the company reported a loss per share of $0.46. Rising operating expenses contributed to an EBIT loss of $21 million, a shortfall slightly larger than Stifel's estimate of a $19 million EBIT loss. Stifel maintained a Hold rating on the stock and set a price target of $9.00, citing concerns around cash burn. The report noted that gross margins exceeded expectations, even as the aggregate financial results prompted a negative market reaction.

Takeaway

The insider purchase by a company director comes against a backdrop of revenue growth paired with ongoing operating losses and heightened investor scrutiny. The Form 4 disclosure confirms the director-level buy and updated shareholding, while recent quarterly results and an analyst Hold underscore both opportunities and financial challenges the company faces as it manages margins and cash flow.


Note: This article reports facts from the Form 4 disclosure and the companys published fourth-quarter 2025 results and related analyst commentary. It does not offer investment advice.

Risks

  • Continued cash burn and higher operating expenses could pressure the company's financial position and ability to fund operations without additional capital - this impacts investors and the healthcare/medical device sector.
  • Negative market reaction to mixed financial results indicates sensitivity in the stock, which may increase volatility for current and prospective shareholders.
  • The share price has declined more than 52% over the last year and traded near a 52-week low, reflecting persistent market skepticism and valuation risk.

More from Insider Trading

Nature's Sunshine Accounting Chief Sells $98,800 of Stock as Company Posts Quarterly Beat Mar 16, 2026 Horizon Kinetics Executes Minimal Purchase of Texas Pacific Land While Valuation Debate Persists Mar 16, 2026 Park-Ohio Director Sells 2,000 Shares; Stock and Outlook Show Mixed Signals Mar 16, 2026 RENN Fund Executive Adds to Personal Stake with $3,458 Purchase Mar 16, 2026 Claritev CFO Buys $22,997 of Stock as Company Reports Modest Revenue Gain Mar 16, 2026